3Opal SM,Esmon CT.Bench-to-bedside review:functional relation ships between coagulation and the innate immune responseand their respective roles in the pathogenesis of sepsis[J].Crit Care,2003,7:23-38.
4Landry DW,Oliver JA.The pathogenesis of vasodilatory shock[J].N Engl J Med,2001,345:588-595.
6Baker CC,Chaudry IH.Evaluation of factors affecting mortalituy rate after sepsis in a murine cecal ligation and puncture model[J].Surgery,1992,94(2):331.
7Elliott J,Mosmann T.IL-10 inhibits cytokine production,vascular leakage and swelling during T-helper cell-induced delayed-type hypersensitivity[J].Immunol,1994,153(9):396.
8Bogdan C,Vodovotz Y,Nathan C.Macrophage deactivation by IL-10[J].J Exp Med,1991,174(8):1549.
9Ralph P,Nakoinz I,Sampson-Johannes A,et al.T lymphocyte in hibitor of human blood cell production of IL-1 and tumor necrosis factor[J].J Immunol,1992,148(4):808.
5Pierce JD, McCabe S, White N, et al. Biomarkers: an important clinical assessment tool[J]. Am J Nurs, 2012, 112(9): 52-58.
6Watkins RR, Lemonovich TL. Serum proealcitonin in the diagnosis and management of intra-abdominal infections [J]. Expert Rev Anti Infect Ther, 2012, 10(2): 197-205.
7Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis [J]. Diagn Microbiol Infect Dis, 2012, 73(3): 221-227.
8Schuetz P, Christ-Crain M, Miller B. Procalcitonin and other biomarkers for the assessment of disease severity and guidance of treatment in bacterial infections [J]. Advances in Sepsis, 2008, 6 (3): 82-89.
9Magadia RR, Weinstein MP. Laboratory diagnosis of bacteremia and fungemia[J]. Infect Dis Clin North Am, 2001, 15(4): 1009-1024.
10Agarwal R, Schwartz DN. Proealcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review [J]. Clin Infect Dis, 2011, 53(4): 379-387.
